Speeding up the access to and uptake of innovative Mpox vaccines

HaDEA has published the EU4Health call for tenders HADEA/2025/OP/0013- Speed up the access to and/or uptake of innovative Mpox vaccines. 

The objective of this call for tender will be to strengthen the scientific evidence on the immune response provided by the Modified Vaccinia Ankara virus-Bavarian Nordic (MVA-BN) vaccine, with particular emphasis on the need and optimal timing of booster doses. Therefore, the purpose of this call for tenders will be to purchase clinical services for clinical research and/or other equivalent scientific activities to evaluate and compare the immunogenicity of a booster dose of MVA-BN vaccine considering different routes of administration, namely intradermal and subcutaneous injection, and the appropriate timing of the booster dose. The activities under this call are expected to include a Phase II and/or Phase III clinical trial(s).  

The results of the clinical study(ies)/trial(s) should be able to contribute to the development and refinement of vaccination strategies to be adopted by public health authorities, as well as to provide further evidence for the European Commission and EU countries to consider when developing relevant policies, e.g. on stockpiling initiatives, and/or the feasibility of dose-sparing strategies for Mpox vaccination during shortages.

Indicative budget: €4 900 000